Ignite Creation Date:
2024-05-06 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04719481
Status:
UNKNOWN
Last Update Posted:
2021-06-23
First Post:
2021-01-06
Brief Title:
Pravastatin Reduces Acute Phase Response of Zoledronic Acid
Sponsor:
Peking University Third Hospital
Organization:
Peking University Third Hospital
Study Overview
Official Title:
The Reduction Effect of Oral Pravastatin on Acute Phase Response of Intravenous Zoledronic Acid a Real-world Study
Status:
UNKNOWN
Status Verified Date:
2021-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acute phase response APR is one of the most common adverse events in osteoporosis with zoledronic acid treatment Its reported that this reaction is related to the blockade of the mevalonate pathway leading to isopentenyl pyrophosphate IPP accumulation And the latter can active γδT cells in the circulation resulting in inflammatory cytokine release Statins can inhibit the conversion of HMG-CoA to mevalonate that may reduce the accumulation of IPP Therefore it is possible that statins can be taken in advance to reduce APR caused by zoledronic acid infusion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None